Back to search results

Atorvastatin for Cerebrovascular Reactivity in Mild Cognitive Impairment

This study is looking at how atorvastatin (a common cholesterol-lowering medication) affects blood flow in the brain for people with mild cognitive impairment (MCI). MCI means you have some memory or thinking problems, but not full dementia. Researchers want to see if taking 40 mg of atorvastatin every night can improve how well blood vessels in the brain react, which could help with blood flow. You might be able to join if you are between 60 and 95 years old, have MCI, and haven't taken statins in the last 6 months. The main goal is to measure changes in brain blood vessel reactivity using an MRI scan after 12 weeks. The current status of this study is unclear, and it plans to enroll 20 participants.

Study design
This is an interventional study where all 20 participants will receive atorvastatin in an open-label manner, meaning both you and the study staff will know you are taking the drug.
What's involved
You would take a 40 mg atorvastatin pill every night. You will have an MRI scan at the beginning of the study and again after 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your brain blood vessel reactivity will be measured at 12 weeks after starting the medication.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04765137

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

Recruiting
PHASE2Ages 60–95InterventionalTreatment
Johns Hopkins University
~20 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Atorvastatin Oral Tablet

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change of MRI whole brain cerebrovascular reactivity (wbCVR)
Measured over Baseline and 12 weeks

Conditions

Mild Cognitive Impairment

Explore related trials

Mild cognitive disorder

NCT04765137

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Johns Hopkins University, Bayview Medical Center

    Baltimore, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Paul Rosenberg, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Samantha Horn
[email protected]
410-550-9020
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0.
Memory, processing speed, executive function, language - cognitive scores \> 1.5 standard deviations below age-education norms.
Not demented by history.
Not taking statins currently or in the last 6 months.
Cognitive/functional impairment not likely due to another neurological disease or delirium.

Exclusion

Taking a statin currently or have taken a statin in the last 6 months.
Contraindications to taking a statin.
Transplant patient taking cyclosporine.
Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).
Diagnosis of dementia by history.
Current diagnosis of substance abuse.
History of stroke or myocardial infarction in past 6 months.
History of HIV.

What this trial measures

  • Change of MRI whole brain cerebrovascular reactivity (wbCVR)Baseline and 12 weeks

    MRI based CVR is a newer technique that measures dilatory function of the microvessels which have been shown to be superior to measurement of Cerebral blood flow (CBF) and have also been shown to be low in participants with MCI.